Whey Protein Micelles and Thermogenesis in Overweight Subjects (Thermowhey)
Whey Protein Micelles and Thermogenesis In Overweight Subjects
The main objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels.
It will be a randomized crossover double-blind design conducted in 20 subjects.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Primary objective and outcome:
The primary objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels (WPM).
Secondary objectives and outcomes:
Explore the mechanism of action of WPM on thermogenesis including:
Protein turnover in response to the dose and the source of protein (WPM versus casein) Insulinemic and glycemic response to the dose and source of protein (WPM versus casein)
Design: The proposed study is a randomized double-blind, placebo-controlled, single center, crossover design.
At the start of the study, subjects will be randomly assigned to 4 different groups in a crossover design, where they will be asked to consume a beverage containing Product 1: 0g of protein (maltodextrin control) Product 2: 30g of WPM Product 3: 50g of WPM Product 4: 50g of micellar casein (MC) Number of subjects: The number of subjects will be 15. Sufficient subjects should be recruited to provide a 30% drop-out rate. Therefore 20 subjects will be needed including drop-outs.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Overweight (BMI range between 25.0 and 29.9 kg per m2 Healthy Having obtained his/her subjects over 20 year informed consent.
Exclusion Criteria:
Chronic or acute diseases affecting protein metabolism (diabetes, renal insufficiency, CVD, liver disease), dyslipidemia History of varicose or venous stases Recent major surgery (3 months) History of major gastro-intestinal surgery (gastric bypass, intestinal resection etc…) Malabsorption disorders History of cancer within the past year Significant weight loss during the last 3 months Food allergies, especially cow milk protein. Pregnancy or lactation Special diets especially vegetarian, high protein (≥ 1.6 g/kg) or weight loss program Abnormal Food Frequency Questionnaire Aversion to vanilla or chocolate aromas Smoking Moderate to intense physical activity > 2 hours/week Hematocrit <40 for males and < 36 for females Blood donation within 3 months of study start and 3 months after study end Regular consumption of medication and supplements i.e. any treatment affecting thermogenesis or nutrient metabolism in general such as corticosteroids, insulin, androgens, antibiotics and nutritional supplements (multivitamins, protein shakes).
Have a high alcohol consumption (more than 1 drink/day) Consumption of illicit drugs Subject who cannot be expected to comply with the study procedures, including consuming the test products.
Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Control (WPM 0)
400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
|
43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
|
|
Aktiv komparator: WPM 30
400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
|
16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
85.0 % maltodextrin,15.0%
fat, 0% WPM
|
|
Aktiv komparator: WPM 50
400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
|
43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
85.0 % maltodextrin,15.0%
fat, 0% WPM
|
|
Aktiv komparator: MC 50
400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
|
43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
85.0 % maltodextrin,15.0%
fat, 0% WPM
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
thermic effect of food
Tidsram: 7 hours from baseline measurements
|
gas exchanges through indirect calorimetry
|
7 hours from baseline measurements
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Whole body protein turnover
Tidsram: 7 hours from baseline
|
protein synthesis and breakdown
|
7 hours from baseline
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Maurice Beaumont, MD, PhD, Société des Produits Nestlé (SPN)
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 10.19.MET
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på WPM 30
-
Alain KaelinUniversity of Applied Sciences and Arts of Southern Switzerland; Clinical...Rekrytering
-
Mayo ClinicAvslutadDarrningFörenta staterna
-
National Yang Ming UniversityAvslutadFörändringar i central kontroll av axelmuskler hos kontorsanställda med ospecifik kronisk nacksmärtaTranskraniell magnetisk stimulering | Ospecifik kronisk nacksmärta | Neuromuskulär kontroll | KontorsarbetareTaiwan
-
University of Texas at AustinAvslutad
-
Chang Gung Memorial HospitalAvslutad
-
Kanuni Sultan Suleyman Training and Research HospitalEngin OralAvslutad
-
The Cleveland ClinicAktiv, inte rekryterandeKonsumtion av orala konstgjorda sötningsmedel på trombocytaggregation och polyolutsöndring (COSETTE)Kardiovaskulär riskfaktorFörenta staterna
-
Rush University Medical CenterIndragenKronisk smärta i ländryggen | Perifer neuropati | CRPS
-
University Malaysia SarawakUniversity of MalayaAvslutad
-
Clinica Universidad de Navarra, Universidad de...Rovi Pharmaceuticals Laboratories; Equipe EnervitAvslutadÖvervikt | Diabetes typ 2Spanien